What is the benefit of using endogenous metabolic modulator compositions to tackle complex diseases?

Project specs

Format

2D/3D

Contact

Axcella Health

Length

01:00

Summary

Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

How do you turn cattle manure into a valuable…

Innovative, research-focused agricultural SME focused on tackling greenhouse gas emissions…